

December 20, 2024

News Release

Company: Olympus Corporation

Yasuo Takeuchi, Director, Representative Executive Officer, Executive Chairperson and ESG Officer

(Code: 7733, Prime, Tokyo Stock Exchange)

Contact: Takaaki Sakurai, Vice President, Investor Relations

TEL: +81-3-3340-2111

Notice: Concerning Change of Executive Officer

Olympus Corporation ("Olympus") hereby announces that the Board of Directors held today has tentatively decided to change the executive officer for Chief Technology Officer as described below. It is scheduled to be decided formally in the Board of Directors in February 2025 and to take effect on April 1, 2025.

1. Reason for change

Having made significant contributions to Olympus in various regional and global managerial roles since 2004, André Roggan had announced his decision to retire in 2025. André will be succeeded by Syed Naveed who brings extensive global experience in the MedTech industry, with expertise in leading R&D, Innovation, Operations, Emerging Markets, Strategy and Portfolio management. His work has supported key business units, including GI Endotherapy, Respiratory, Urology, and Critical Care. Throughout his career, Syed has also built and led high-performing, globally distributed teams.

Syed joined Olympus in December 2022 as the Global Head of Single Use Endoscopy, where he successfully built a new team, strengthened internal capabilities, and piloted new processes and governance frameworks to ensure efficient and reliable product development. In February 2024, his role expanded to include leadership of R&D for Therapeutic Solutions Division (TSD), supporting a critical area of our business.

At Olympus, we remain committed to elevating the standard of patient care by making people's lives healthier, safer, and more fulfilling. In line with this mission, we continue to prioritize sustainability, ensuring quality and compliance with laws and regulations while fostering innovation to advance next-generation developments.

In his expanded role, Syed will drive focused innovation and deliver predictable execution in new product development, helping to elevate the standard of patient care and fuel Olympus' growth.

2. Names and job titles of newly appointed and retiring executive officer

(1) Newly appointed executive officer

Name	Current job titles	New job titles after April 1, 2024
Syed Naveed	Senior Vice President, Therapeutic Solutions Division Development Head, Olympus Corporation	Executive Officer and Chief Technology Officer

(2) Departure executive officer

Name	Current job titles
André Roggan	Executive Officer and Chief Technology Officer

3. Career summary of newly appointed executive officer

Syed Naveed

Date of Birth:	September 5, 1973	
Career summary:	August 1996	Indian Institute of Science
	September 2000	Spectra Technologies Inc
	September 2003	Boston Scientific Corporation
	January 2009	Program manager & Principal Engineer, Boston Scientific Corporation
	June 2011	Senior R&D Program Manager, New Product Development, Boston Scientific Corporation
	September 2013	Head of Regional R&D, Endoscopy Business Unit, Boston Scientific Corporation
	January 2016	Head of Strategic Innovation Group (Endoscopy Business Unit), Boston Scientific Corporation
	October 2018	Senior Director R&D, Urology & Critical Care, Becton, Dickinson and Company
	December 2019	Worldwide Vice President R&D, Urology & Critical Care, Becton, Dickinson and Company
	December 2022	Joined Olympus Corporation of the Americas Senior Vice President, Single Use Endoscopy Development Head, Olympus Corporation (Present)
	February 2024	Senior Vice President, Therapeutic Solutions Division Development Head, Olympus Corporation (Present)
April 2025	Executive Officer, Olympus Corporation (plan) Chief Technology Officer, Olympus Corporation (plan)	
Number of shares of the Company held (Note) (Of which, the number of shares to be delivered under the stock compensation plan):	12,284 (11,358)	

(Note) “Number of shares of the Company held” indicates the number of shares held as of September 30, 2024. It also includes the number of shares each candidate holds through the Employees’ Shareholding Association of the Company, his/her own equity interest held through a company managing stock compensation of the Company as well as the number of shares to be delivered under the stock compensation plan.